Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INMUNOSUN: Sunitinib in mRCC post-immunotherapy
NCT03066427Phase 2Completed
- Sponsor
- SOGUG
- Start
- May 2017
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sunitinib in clear cell renal cell carcinoma (ccRCC), sponsored by SOGUG. Started May 2017; status: completed.
02
Drugs
sunitinib
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT03066427.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03066427.